Skip to content
Since its founding in 1920, the National Health Council (NHC) has brought diverse organizations together to forge consensus and drive patient-centered health policy in […]
Q&A with National Health Council: Driving patient-centred policy Read More »
“Biotechnology innovation is advancing at an unprecedented pace, delivering new treatments and cures that offer long-awaited hope to patients and their families,” said Karin
BIO Coffee Chat: Price controls like MFN harm access, increase costs Read More »
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
The inaugural BIO Investment and Growth (BIG) Summit was a chance for leaders in the biotech industry to catch up on domestic and international
BIG Summit themes: Resilient investment, MFN threat, patients in the center Read More »
Washington’s healthcare policy landscape is constantly evolving, and 2026 is shaping up to be another consequential year for the biotech industry. Some developments are
BIG Summit panel breaks down risks and opportunities coming out of DC Read More »
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center of the debate. Working
The hidden layer of PBMs: What a recent investigation reveals Read More »
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care Read More »
We could be in for another big year of biotech M&A. A busy 2025, in both licensing and M&A in biopharma, saw over 4,000
BIG Summit: Experts see signs of M&A momentum in 2026 Read More »
The Medicare drug price “negotiation” process has entered its third year, with some evolution but continued complexity for patients and patient organizations. This year,
BIO Patient Advocacy Coffee Chat: Act now to be heard on CMS drug pricing Read More »
